Windtree Receives Offer for Its Preclinical Oncology Drug Candidate

Core Viewpoint - Windtree Therapeutics, Inc. has received a non-binding letter of intent for the sale of its preclinical oncology aPKCi inhibitor platform, which includes an upfront payment of $7.0 million and potential milestone payments totaling up to $130.0 million, along with high single-digit royalties that could reach up to $1.5 billion over the drug's lifecycle [1][2][3]. Group 1 - The agreement allows for additional options to acquire the Company's cardiovascular clinical and preclinical stage drug candidates and includes a manufacturing agreement for Evofem Biosciences' FDA-approved product [2]. - The Company has a 21-day window to finalize the oncology aPKCi portion of the transaction [2]. - The CEO of Windtree stated that the preclinical oncology aPKCi assets are not viewed as core to the Company's future vision, but the transaction may provide non-dilutive cash and a lucrative revenue stream through milestones and royalties [3]. Group 2 - Windtree Therapeutics aims to become a revenue-generating company across multiple growing industries to achieve overall profitability [4].